Copyright 2024
| PMID | Allele | Disease | Population | Drug Names | SNP | Class | Sentence |
|---|---|---|---|---|---|---|---|
| 31529689 | HLA (HLA) | neuromyelitis optica | NA | NA | NA | unclassified | |
| t-cell depleted hla-haploidentical hsct in a child with neuromyelitis optica. | |||||||
| 11290782 | HLA (HLA) | pathologic processes | NA | NA | NA | unclassified | |
| these findings highlight the immunomodulatory role that hla-g2, -g3, and -g4 proteins will assume during physiologic or pathologic processes in which hla-g1 expression is altered. | |||||||
| 28442521 | HLA-DR (HLA-DR) | neonatal sepsis | NA | NA | NA | unclassified | |
| in addition to acute-phase proteins, cell surface antigens such as cd11b, cd64, and hla-dr should be used in routine investigations for the early diagnosis of neonatal sepsis. | |||||||
| 11298622 | HLA-DR (HLA-DR) | acute-phase response | NA | NA | NA | only_studied | |
| phytohaemagglutinin (pha) skin test reactivity, monocyte human leucocyte antigen (hla) dr expression and the extent of the acute-phase response, by determination of white blood cell count and differentiation, plasma interleukin (il) 6 levels and body temperature in the perioperative period, were examined. | |||||||
| 24101016 | HLA-DR (HLA-DR) | acute-phase response | NA | cortisol | NA | unclassified | |
| the immunological response was measured by means of leukocyte counts, hla-dr expression on monocytes, the acute-phase response by means of c-reactive protein (crp), interleukin-6 (il-6), and interleukin-8 (il-8), and the stress response was measured by cortisol, growth hormone, and prolactin. | |||||||
| 27087592 | HLA-CLASS I (HLA CLASS II) | cancer testis | NA | NA | NA | unclassified | |
| the cell lines express numerous cancer testis antigens, surface molecules involved in immune evasion but low levels of hla class i molecules. | |||||||
| 30530992 | HLA (HLA) | cancer testis | NA | NA | NA | unclassified | |
| used mice with human tcrab and hla gene loci to discover cd4+ tcrs of optimal affinity for cancer testis antigen (cta) ny-eso-1. | |||||||
| 32102902 | HLA-A*02 | cancer testis | NA | NA | NA | unclassified | |
| we determined tcr-peptide-hla crystal structures and, using a single-chain peptide-hla phage library, we generated peptide specificity profiles for three newly identified human tcrs specific for the cancer testis ag ny-eso-1157-165-hla-a2. | |||||||
| 32157447 | HLA-A*02 | cancer testis | NA | NA | NA | unclassified | |
| cancer testis antigen cyclin a1 harbors several hla-a*02:01-restricted t cell epitopes, which are presented and recognized in vivo. | |||||||
| 32532817 | HUMAN LEUKOCYTE ANTIGEN (HUMAN LEUKOCYTE ANTIGEN) | cancer testis | NA | NA | NA | unclassified | |
| t cell receptor interactions with human leukocyte antigen govern indirect peptide selectivity for the cancer testis antigen mage-a4. | |||||||
Copyright 2024